Skip to content
Parker Institute for Cancer Immunotherapy
Search Close

Scott James, MD, PhD

Parker Bridge Fellow and Hematology/Oncology Fellow


Chimeric antigen receptor-modified T cells have demonstrated clinical successes in B cell malignancies and are currently being evaluated in other malignancies targeting novel antigens. I am interested in synthetic biology approaches to modify T cell behavior and function with the goal of improving the clinical efficacy and tissue selectivity of adoptive cellular immunotherapy. I additionally am interested in the application of synthetic biology approaches, including chimeric antigen receptors, to improve graft vs. leukemia/lymphoma responses while decreasing graft vs. host responses in the transplant setting.

Education & Training

  • 2002: University of California at Los Angeles, BS, Biochemistry, Summa Cum Laude
  • 2009: University of Washington, PhD, Immunology
  • 2011: University of Washington School of Medicine (MSTP), MD
  • 2011-2014: University of Washington, Residency, Internal Medicine

Awards & Honors

  • 2017: Post-Graduate Parker Institute for Cancer Immunotherapy (PICI) Pilot grant; Amy Strelzer Manasevit Research Program Award
  • 2016: ASCO Young Investigator Award
  • 2013: Gold Humanism Award
  • 2008: Cancer Research Institute training grant
  • 2006: ARCS (Achievement Awards for College Scientists) Scholarship
  • 2005: Poncin Fellowship
  • 2002: University of Washington Medical Scientist Training Program; Phi Beta Kappa; UCLA Departmental Highest Honors in Biochemistry; UCLA, Summa Cum Laude; UCLA College Honors; Geissman Award for Excellence in Organic Chemistry
  • 2001: Litton Industries Research Scholarship
  • 2000: UCLA Department of Chemistry and Biochemistry Summer Research Award; Beckman Research Scholarship; Distinguished Bruin Award
  • 1999: de Vellis Memorial Scholarship